Inactive Instrument

Press Releases Novartis AG Swiss Exchange

Equities

CH0012005267

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

02:00pm	Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	RE
05-31	NOVARTIS AG : UBS reiterates its Buy rating	ZD

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease	05-31	PU
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML	05-31	GL
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	05-30	GL
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	05-25	GL
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo	05-25	GL
Amgen And Sandoz Settle Denosumab BPCIA Litigation	05-20	AQ
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash	05-16	GL
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	05-15	GL
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML	05-13	AQ
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	05-10	AQ
Novartis : enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline	05-02	PU
Novartis : Q1 2024 impact and sustainability update	04-30	PU
European Commission authorises one of first ustekinumab biosimilars in Europe	04-26	AQ
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	04-24	GL
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	04-23	AQ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	04-23	GL
Novartis: Q1 Earnings Snapshot	04-23	AQ
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	04-23	GL
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	04-17	GL
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	04-15	GL